ArticleDiscover oncology2026
Systematic analysis of the mitophagy scoring system in the prognosis and immunotherapy of HCC patients.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMitophagy plays a vital role in hepatocellular carcinoma (HCC) progression. This study aims to construct a mitophagy-related scoring system and evaluate its prognostic value, association with tumor immune activity, and gene mutation profiles in HCC patients, thereby advancing personalized diagnosis and treatment.
methodsCopy number variation (CNV) data of mitophagy regulators from TCGA and ICGC databases were integrated for consensus clustering. Principal component analysis (PCA) was employed to establish a mitophagy scoring system based on mitophagy clusters, gene clusters, and clinical outcomes. Kaplan-Meier survival analysis, Spearman correlation, and immune infiltration algorithms (CIBERSORT, ssGSEA) were used to assess clinical relevance, prognosis, and immunotherapy sensitivity. Tumor mutation burden (TMB) was combined with mitophagy scores for refined prognosis prediction.
resultsThree distinct mitophagy clusters (A, B, C) and gene clusters (A, B, C) were identified, showing significant differences in prognosis, immune cell infiltration (19 immune cell types, p < 0.05), and mutation profiles. The mitophagy scoring system stratified patients into high- and low-score groups. High-score patients exhibited better overall survival (p < 0.001), higher immune checkpoint expression (PD-1, CTLA4; p = 0.015 and p = 0.0007), and greater sensitivity to immunotherapy. Low-score patients had higher TP53 mutation rates (55%) and poorer outcomes. Combining mitophagy scores with TMB further improved prognostic accuracy (p < 0.001).
conclusionThe mitophagy scoring system serves as a robust prognostic biomarker and predictor of immunotherapy response in HCC, offering insights into tumor heterogeneity and clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.